4retire
2年前
Just listened to the OPRX conference call. They've showed decreases in revenues the last two quarters and are forecasting another drop in Q1's (about 11%) revenue. They are forecasting an increase of over 10% growth for this year. That means robust revenues are to be recognized in Q's 2, 3 and 4.
Keep in mind OptimizerX is targeting a $10 billion market. If we, in fact, have the best solution for a customer's ROI, it has to be realized in increased volumes and profits someday. The pace, or lack thereof, is maddening.
Of particular concern is the increased costs that continue to damage the profitability of this company. The COO said costs will increase in Q1/23 as revenues are forecasted to shrink in that quarter . Noteworthy is that they are doing buybacks of their stock. They reduced the share count from barely over 18 million to just above 17 million. This was a 7% reduction but cost the bottom line over $1.2 million. One has to ask why this is deemed significant when the stock has lost so much value over the last 12 months. Wouldn't a profitable OPRX seem more desirable to own than one with a million less shares? This puzzles me.
whytestocks
4年前
JUST IN: $OPRX OptimizeRx Expects Record Revenue Exceeding $10.0 Million in Q3 2020, up 100%
ROCHESTER, Mich., Oct. 13, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, reported preliminary unaudited revenue for its third quarter ended September 30, 2020. Revenue f...
Find out more OPRX - OptimizeRx Expects Record Revenue Exceeding $10.0 Million in Q3 2020, up 100%
whytestocks
4年前
News: $OPRX OptimizeRx Sales Momentum Continues with Two New Enterprise-level Engagements Added to its Digital Health Platform
ROCHESTER, Mich., July 07, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies and payers, has secured two new SaaS-based enterprise-level engagements that provide the full spectrum of access to the company...
Read the whole news OPRX - OptimizeRx Sales Momentum Continues with Two New Enterprise-level Engagements Added to its Digital Health Platform
whytestocks
5年前
News: $OPRX OptimizeRx Sales Pipeline Up 79% to $84 Million in 2019; Company Reiterates Strong Q4 and 2020 Outlook
ROCHESTER, Mich., Dec. 09, 2019 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health solutions for pharmaceutical companies, payers, medtech and medical associations, reported its sales pipeline, which is comprised of outstanding request for proposal...
Got this from OPRX - OptimizeRx Sales Pipeline Up 79% to $84 Million in 2019; Company Reiterates Strong Q4 and 2020 Outlook
whytestocks
6年前
News: $OPRX OptimizeRx Sets First Quarter 2019 Conference Call for Wednesday, May 8, 2019 at 4:30 p.m. ET
ROCHESTER, Mich., April 26, 2019 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (NASDAQ: OPRX), a leading provider of digital health messaging for the pharmaceutical industry, will hold a conference call on Wednesday, May 8, 2019 at 4:30 p.m. Eastern time to discuss results for the first quarter ...
Read the whole news https://marketwirenews.com/news-releases/optimizerx-sets-first-quarter-2019-conference-call-for-wednesday-may-8-2019-at-4-30-p-m-et-8066294.html
gjervis
6年前
$OPRX
Their 8K says alot!! Change of control bonus!! what are they hinting at?
“As a universal and new change, the Company’s bonus plan was amended to include a change of control bonus ranging from $0 to up to $750,000, depending on the transaction price, for each of these four executive officers, if a change of control transaction occurs in either 2018 or 2019.”
4retire
7年前
This should be a great move! Part of the release:
ROCHESTER, Mich., June 19, 2018 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (NASDAQ: OPRX), a leading global provider of digital health messaging for the pharmaceutical industry, has uplisted to the Nasdaq Capital Market, with its common stock to commence trading on the exchange beginning Friday, June 22, 2018 under the symbol, “OPRX.”
“Joining the Nasdaq Capital Market represents another major milestone for OptimizeRx, following a number of significant events over the last few months,” said company CEO, William Febbo. “After announcing the expansion of our digital health messaging services beyond the ambulatory setting and into hospitals, we reported our sixth consecutive quarter of record revenue. This was soon followed by our first international expansion into Europe with a major partner, building upon our reach to more than half of the ambulatory patient market in the U.S.
“As we continue to demonstrate high ROI from the marketing spend of our pharma clients and strengthen our network of EHR partners, we expect our Nasdaq listing to further elevate our corporate profile, enhance liquidity for our investors, and broaden our shareholder base.”